drugset / Trial / NCT06492863
Gene Therapy(FT-003) for Wet AMD
Phase 1/2
Recruiting
78 enrolled
Frontera Therapeutics
Beijing Hospital · collabPeking Union Medical College Hospital · collabThe First Affiliated Hospital of Soochow University · collabTianjin Medical University Eye Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.
Timeline
- Start
- 2023-08-15
- Primary completion
- 2024-10-15
- Completion
- 2028-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT-003 | Unknown | — | Other |